drugset / Trial / NCT05844228

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

NCT05844228

Phase 1 Completed 28 enrolled Vir Biotechnology, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable

Timeline

Start
2023-06-01
Primary completion
2025-03-01
Completion
2025-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject VIR-2218 Small interfering RNA (siRNA) Subcutaneous